Frontiers in Cardiovascular Medicine (Dec 2022)
Corrigendum: Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants
- Hongjie Chen,
- Jiepeng Chen,
- Fuping Zhang,
- Yuanhui Li,
- Ronghua Wang,
- Qiang Zheng,
- Xu Zhang,
- Jun Zeng,
- Feng Xu,
- Yiguang Lin,
- Yiguang Lin,
- Yiguang Lin
Affiliations
- Hongjie Chen
- Department of Traditional Chinese Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- Jiepeng Chen
- Sungen Bioscience Co. Ltd., Shantou, China
- Fuping Zhang
- Department of Pharmacy, Shenyang Red Cross Hospital, Shenyang, China
- Yuanhui Li
- Guangzhou Center, Sinopharm Group Pharmaceutical Co., Ltd., Guangzhou, China
- Ronghua Wang
- Sungen Bioscience Co. Ltd., Shantou, China
- Qiang Zheng
- Sungen Bioscience Co. Ltd., Shantou, China
- Xu Zhang
- Sungen Bioscience Co. Ltd., Shantou, China
- Jun Zeng
- Sungen Bioscience Co. Ltd., Shantou, China
- Feng Xu
- Antithrombotic & Thrombolytic Innovative Drug Research Center, Shenyang Pharmaceutical University, Shenyang, China
- Yiguang Lin
- Department of Traditional Chinese Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- Yiguang Lin
- The Central Laboratory, First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
- Yiguang Lin
- School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia
- DOI
- https://doi.org/10.3389/fcvm.2022.1076420
- Journal volume & issue
-
Vol. 9
Abstract
No abstracts available.Keywords
- nattokinase
- atherosclerosis
- hyperlipidaemia
- anti-atherogenic drug
- lipid lowering effect
- retrospective study
